Abstract 1748P
Background
Obesity has been recognised as one of the main risk factors for non- communicable diseases including cancer. WHO European report suggests that obesity affects 30% of children in Europe. Unhealthy diet is one of the most important determinants of childhood obesity, a condition that has become very prevalent in the south of Europe. Consumption of sugar-sweetened beverages (SSBs) influence childhood obesity and food advertisement is one of the strongest determinants of SSB consumption.
Methods
A multidisciplinary panel of clinicians from the South of Europe (Cyprus, Greece, Italy, Malta, Spain and Portugal) critically reviewed the available legislation and recommendations on SSB advertisements, in native language. The website of relevant national societies (Cardiovascular, Diabetic, Oncology, Paediatric and Stroke) was reviewed. Herein we present the recommendations from Oncology national societies.
Results
The countries in study have national legislations on SSB advertisements following EU directives with Spain having the most comprehensive regulatory framework. None of the oncology societies had recommendations on SSB consumption from children. The Spanish oncology society (SEOM) recognised obesity as risk factor for developing cancer and a close collaboration with the Spanish Association for the study of obesity is suggested. The Portuguese Society of Oncology (SPO) provides general guidance on the role of food and nutrition in cancer development. In Greece and Cyprus sporadic publications from the oncology society (HeSMO) on the preventive role of diet was noticed with no concrete guidance. Italian Oncology society (AIOM) has published on the role of nutritional support for cancer patients but the preventive role of healthy diet on childhood obesity is not available. European society of Medical Oncology links to IARC prevention strategies in the society website.
Conclusions
Recommendations on healthy diet to tackle childhood obesity, including SSB advertisement, from national medical societies in South Europe is fragmented. Oncology societies should join forces with other medical societies to increase awareness of childhood obesity and implement measures to address the phenomenon.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23